QURE
Price
$58.00
Change
-$1.99 (-3.32%)
Updated
Oct 17 closing price
Capitalization
3.57B
11 days until earnings call
RPRX
Price
$37.01
Change
+$0.67 (+1.84%)
Updated
Oct 17 closing price
Capitalization
16B
18 days until earnings call
Interact to see
Advertisement

QURE vs RPRX

Header iconQURE vs RPRX Comparison
Open Charts QURE vs RPRXBanner chart's image
uniQure
Price$58.00
Change-$1.99 (-3.32%)
Volume$2.26M
Capitalization3.57B
Royalty Pharma
Price$37.01
Change+$0.67 (+1.84%)
Volume$2.37M
Capitalization16B
QURE vs RPRX Comparison Chart in %
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QURE vs. RPRX commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a Hold and RPRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (QURE: $58.00 vs. RPRX: $37.01)
Brand notoriety: QURE and RPRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 57% vs. RPRX: 56%
Market capitalization -- QURE: $3.57B vs. RPRX: $16B
QURE [@Biotechnology] is valued at $3.57B. RPRX’s [@Biotechnology] market capitalization is $16B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 0 FA rating(s) are green whileRPRX’s FA Score has 1 green FA rating(s).

  • QURE’s FA Score: 0 green, 5 red.
  • RPRX’s FA Score: 1 green, 4 red.
According to our system of comparison, RPRX is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 5 TA indicator(s) are bullish while RPRX’s TA Score has 5 bullish TA indicator(s).

  • QURE’s TA Score: 5 bullish, 5 bearish.
  • RPRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RPRX is a better buy in the short-term than QURE.

Price Growth

QURE (@Biotechnology) experienced а -5.78% price change this week, while RPRX (@Biotechnology) price change was +2.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

QURE is expected to report earnings on Oct 29, 2025.

RPRX is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RPRX($16B) has a higher market cap than QURE($3.57B). QURE YTD gains are higher at: 228.426 vs. RPRX (47.913). RPRX has higher annual earnings (EBITDA): 1.93B vs. QURE (-119.56M). RPRX has more cash in the bank: 1.49B vs. QURE (377M). QURE has less debt than RPRX: QURE (66.7M) vs RPRX (8B). RPRX has higher revenues than QURE: RPRX (2.31B) vs QURE (14.3M).
QURERPRXQURE / RPRX
Capitalization3.57B16B22%
EBITDA-119.56M1.93B-6%
Gain YTD228.42647.913477%
P/E RatioN/A17.33-
Revenue14.3M2.31B1%
Total Cash377M1.49B25%
Total Debt66.7M8B1%
FUNDAMENTALS RATINGS
QURE vs RPRX: Fundamental Ratings
QURE
RPRX
OUTLOOK RATING
1..100
2882
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
1
Undervalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
3449
P/E GROWTH RATING
1..100
9156
SEASONALITY SCORE
1..100
4550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RPRX's Valuation (1) in the Pharmaceuticals Major industry is significantly better than the same rating for QURE (74) in the Biotechnology industry. This means that RPRX’s stock grew significantly faster than QURE’s over the last 12 months.

QURE's Profit vs Risk Rating (72) in the Biotechnology industry is in the same range as RPRX (100) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as QURE (100) in the Biotechnology industry. This means that RPRX’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (34) in the Biotechnology industry is in the same range as RPRX (49) in the Pharmaceuticals Major industry. This means that QURE’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's P/E Growth Rating (56) in the Pharmaceuticals Major industry is somewhat better than the same rating for QURE (91) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than QURE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QURERPRX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
64%
Momentum
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
48%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
53%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
49%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
49%
Advances
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 2 days ago
53%
Declines
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 6 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GBLD18.32N/A
N/A
Invesco MSCI Green Building ETF
FPAS25.45N/A
N/A
FPA Short Duration Government ETF
PBTP26.22-0.02
-0.06%
Invesco 0-5 Yr US TIPS ETF
USTB50.96-0.05
-0.10%
VictoryShares Short-Term Bond ETF
HGLB10.04-0.09
-0.90%
Highland Global Allocation Fund

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with NEVPF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
-3.32%
NEVPF - QURE
50%
Loosely correlated
N/A
AXON - QURE
42%
Loosely correlated
+2.84%
LXEO - QURE
39%
Loosely correlated
+9.24%
NAMS - QURE
37%
Loosely correlated
-0.19%
MLTX - QURE
37%
Loosely correlated
-2.77%
More

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
+1.84%
AXON - RPRX
48%
Loosely correlated
+2.84%
MDGL - RPRX
31%
Poorly correlated
-0.73%
DTIL - RPRX
30%
Poorly correlated
+3.92%
ARRY - RPRX
30%
Poorly correlated
-0.17%
QURE - RPRX
29%
Poorly correlated
-3.32%
More